Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
MALE
NCT04536805

Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin

Led by Institut Cancerologie de l'Ouest · Updated on 2025-12-08

44

Participants Needed

12

Research Sites

571 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This phase I/II escalation dose study is assessing the efficacy of the recommended dose of stereotactic re-irradiation (SBRT) of relapses within the prostatectomy bed, potentiated by metformin

CONDITIONS

Official Title

Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Written informed consent before any study procedures
  • Biochemical recurrence at least 2 years after external radiotherapy and hormone therapy for prostate adenocarcinoma treated by radical prostatectomy
  • Local recurrence confirmed by rising PSA (above 0.2 ng/ml with 2 successive tests) and visible lesion on MRI or PET scans
  • No rectal invasion at recurrence
  • Pelvic and prostate MRI evaluation completed
  • No pelvic lymph node or metastatic recurrence confirmed by PET scan
  • WHO performance status 0-1
  • Low, intermediate, or high risk with a single risk factor
  • PSA doubling time greater than 6 months
  • No anti-cancer treatments planned for current relapse
  • Age 18 years or older
  • Life expectancy of at least 5 years
  • Registered with a health insurance system
  • Willing and able to comply with visits, treatment, lab tests, and study procedures
Not Eligible

You will not qualify if you...

  • Metastatic disease including bone, lymph node, or other sites
  • Late radiotherapy urinary or gastrointestinal toxicity grade 2 or higher
  • History of cancer in the past 5 years except for basal cell skin carcinoma
  • Inflammatory bowel disease
  • Contraindications to MRI
  • History of rectal surgery
  • Current treatment for diabetes
  • Creatinine clearance below 45 mL/min
  • Metformin treatment within 3 months before inclusion
  • Severe comorbidities affecting treatment such as active infections needing IV antibiotics, recent unstable angina, myocardial infarction or heart failure hospitalization within 6 months
  • Exacerbation of COPD or respiratory conditions preventing metformin use
  • Conditions increasing risk of lactic acidosis like alcohol abuse or severe heart failure
  • Significant liver disease with Child-Pugh B or C score
  • Acute or chronic tissue hypoxia conditions
  • Bilateral hip prosthesis
  • Use of investigational drugs or participation in other trials within 30 days
  • Known allergy to metformin or its components
  • Inability or unwillingness to swallow oral medications
  • Legal guardianship or restricted liberty
  • Inability to attend medical monitoring for social, psychological, or geographic reasons

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 12 locations

1

Institut de Cancerologie de L'Ouest

Angers, France, 49055

Actively Recruiting

2

CHRU de BREST - HOPITAL MORVAN

Brest, France, 29200

Actively Recruiting

3

Societe de Recherche Oncologique Clinique 37 (Roc 37)

Chambray-lès-Tours, France, 37170

Not Yet Recruiting

4

Centre GEORGES FRANCOIS LECLERC

Dijon, France, 21079

Not Yet Recruiting

5

Clinique Victor Hugo

Le Mans, France, 72100

Not Yet Recruiting

6

Centre OSCAR LAMBRET

Lille, France, 59020

Actively Recruiting

7

Centre LEON BERARD

Lyon, France, 69373

Actively Recruiting

8

Centre Eugene Marquis

Rennes, France, 35042

Not Yet Recruiting

9

Centre Henri Becquerel

Rouen, France, 76038

Not Yet Recruiting

10

Institut de Cancerologie de L'Ouest

Saint-Herblain, France, 44805

Actively Recruiting

11

ICANS - Institut de cancérologie Strasbourg Europe

Strasbourg, France, 67200

Actively Recruiting

12

Chru Bretonneau

Tours, France, 37044

Not Yet Recruiting

Loading map...

Research Team

V

Valentine GUIMAS, MD

CONTACT

N

Nadia ALLAM, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin | DecenTrialz